About the Company
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PGEN News
Precigen, Inc. (I5X.F)
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Cantor ...
Precigen Finalizes Executive Severance Agreements
Precigen, Inc. has finalized new employment agreements with CFO Harry Thomasian Jr. and COO Rutul R. Shah, ensuring they ...
Precigen (NASDAQ: PGEN)
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals ...
Germantown biotech expands manufacturing capacity, headcount ahead of potential product launch
Germantown’s Precigen Inc., a clinical-stage biotech developing gene and cell therapies for cancers and other diseases, is taking steps to get an experimental treatment to regulators for review ...
Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript
Good afternoon and welcome to the Precigen Full-Year 2023 Financial Results and Update Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question ...
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
GERMANTOWN, Md., March 5, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the ...
Precigen Inc
Precigen Inc Bailey Strategic Advisors SECOND QUARTER (NO ACTIVITY) $20,000 Precigen Inc Bailey Strategic Advisors SECOND QUARTER TERMINATION (NO ACTIVITY) $20,000 Precigen Inc Greenberg Traurig LLP ...
Buy Rating Affirmed on Precigen Amid Promising PRGN-2012 Clinical Progress and Financial Stability
Begin your TipRanks Premium journey today. Precigen (PGEN) Company Description: Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology ...
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
GERMANTOWN, Md., March 28, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of ...
Precigen Reports Full Year 2023 Financial Results and Business Updates
March 19, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients ...
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
GERMANTOWN, Md., March 28, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the ...
Loading the latest forecasts...